Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 14, Issue SUPPL.2, 2008, Pages

  Gerlach, Manfred ^a   Riederer, Peter ^a   Double, Kay L ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Animal models; Cell culture; Iron; Neuromelanin; Parkinson's disease; Proteasome

Indexed keywords

FERRIC ION; IRON; NEUROMELANIN; PROTEASOME; UBIQUITIN;

ARTICLE; DOPAMINERGIC NERVE CELL; EXPERIMENTAL MODEL; IRON METABOLISM; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IRON; MELANINS; NERVE DEGENERATION; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

EID: 47049099820     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.04.028     Document Type: Article

References (24)

1. Federow H., Tribl F., Halliday G., Gerlach M., Riederer P., and Double K. Neuromelanin in human dopamine neurons: comparison with pheripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 75 (2005) 109-124
2. Hirsch E., Graybiel A., and Agid Y. Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
3. Jellinger K. Pathology of Parkinson's syndrome. In: Calne D.B. (Ed). Handbook of experimental pharmacology vol. 88 (1989), Springer, Berlin, Heidelberg 47-112
4. Braak E., Sandmann-Keil D., Rüb U., Gai W.P., de Voa R.A., Jansen Steur E.N.H., et al. α-Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol 101 (2001) 195-201
5. Gerlach M., Ben-Shachar D., Riederer P., and Youdim M.B.H. Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J Neurochem 63 (1994) 793-807
6. Berg D., Gerlach M., Youdim M.B.H., Double K.L., Zecca L., Riederer P., et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 79 (2001) 225-236
7. Götz M.E., Double K., Gerlach M., Youdim M.B.H., and Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann NY Acad Sci 1012 (2004) 193-208
8. Sofic E., Riederer P., Heinsen H., Beckman H., Reynolds G.P., Hebenstreit B., et al. Increased iron (III) and total iron content in post-mortem substantia nigra of parkinsonian brain. J Neural Transm 74 (1988) 199-205
9. Gerlach M., Double K.L., Youdim M.B.H., and Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl. 70 (2006) 133-142
10. Lopiano L., Digilio G., Fasano M., Giraudo S., Rizzone M., Torre E., et al. Iron and neuromelanin in Parkinson's disease. J Neural Transm 106 (1999) XXIV
11. Double K.L., Riederer P., and Gerlach M. The significance of neuromelanin for neurodegeneration in Parkinson's disease. Drug News Perspect 12 (1999) 333-340
12. Double K.L., Gerlach M., Schünemann V., Trautwein A.X., Zecca L., Gallorini M., et al. Iron binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66 (2003) 489-494
13. Gerlach M., Trautwein A.X., Zecca L., Youdim M.B.H., and Riederer P. Mössbauer spectroscopic studies of human neuromelanin isolated from the substantia nigra. J Neurochem 65 (1995) 923-926
14. Shima T., Sarna T., Swartz H., Stroppolo A., Gerbasi R., and Zecca L. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med 23 (1997) 110-119
15. Shamoto-Nagai M., Maruyama W., Yi H., Akao Y., Tribl F., Gerlach M., et al. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Transm 113 (2006) 633-644
16. Li J., Scheller C., Koutsilieri E., Griffiths F., Beart P.M., Mercer L.D., et al. Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem 95 (2005) 599-608
17. Offen D., Gorodin S., Melamed E., Hanania J., and Malik Z. Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease. Neurosci Lett 260 (1999) 101-104
18. Nguyen A., Gille G., Moldzio R., Hung S.-T., and Rausch W.-D. Synthetic neuromelanin is toxic to dopaminergic cell cultures. J Neural Transm 109 (2002) 651-661
19. Shamoto-Nagai M., Maruyama W., Akao Y., Osawa T., Tribl F., Gerlach M., et al. Neuromelanin inhibits enzymatic activity of 26 proteasome in human dopaminergic SH-SY5Y cells. J Neural Transm 111 (2004) 1253-1265
20. McNaught J.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179 (2003) 38-46
21. Double K.L., Halliday G.M., Henderson J., Griffiths F.M., Heinemann T., Riederer P., et al. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp Neurol 184 (2003) 530-535
22. Gerlach M., and Riederer. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103 (1996) 987-1041
23. Riederer P., and Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38 (1976) 277-301
24. Halliday G., McRitchie D., Cartwright H., Pamphlett R., Hely M., and Morris J. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci 3 (1996) 52-60